SRPT Share Price Performance
US$21.49
-42.17 (-66.24%)
0.7% undervalued intrinsic discount
US$21.65
Fair Value
Price US$21.49
AnalystConsensusTarget US$21.65
AnalystHighTarget US$37.42
AnalystLowTarget US$5.00
Fair ValueUS$21.65
Share Pricen/a
Sarepta Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 88 Fair Values set on narratives written by author
SRPT Community Narratives
AN
Fair Value
·Fair Value US$21.65 0.7% undervalued intrinsic discount
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
3users have liked this narrative
1users have commented on this narrative
40users have followed this narrative
AN
Fair Value
·Fair Value US$37.42 42.6% undervalued intrinsic discount
Rising Genetic Testing And Precision Medicine Will Unlock New Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$70 69.3% undervalued intrinsic discount
Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Rising Genetic Testing And Precision Medicine Will Unlock New Markets
Key Takeaways Growing adoption of genetic testing, payer acceptance, and expanded infusion networks are driving revenue growth, pricing power, and increased patient access to therapies. Pipeline expansion, external collaborations, and manufacturing scale are positioning the company for diversified growth, improved margins, and long-term earnings gains.Read more
AN
US$37.42
42.6% undervalued intrinsic discount
Fair Value
Profit Margin
31.26%
Future PE
11.02x
Price in 2029
US$47.1
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Key Takeaways Addressing operational delays and administrative complexities in gene therapy could enhance revenue by quickly converting demand into treated patients. Expanding into LGMD and siRNA platforms diversifies revenue, potentially boosting earnings and financial stability.Read more
AN
US$21.65
0.7% undervalued intrinsic discount
Fair Value
Profit Margin
6.09%
Future PE
39.8x
Price in 2029
US$27.13
Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement
Key Takeaways Regulatory scrutiny and operational delays threaten timely access, increase compliance costs, and could pressure margins despite a favorable innovation climate and growing patient base. Overreliance on key products, delayed capacity expansion, and high upfront investments heighten risks of market saturation, revenue concentration, and sustained operating losses.Read more
AN
US$70
69.3% undervalued intrinsic discount
Fair Value
Profit Margin
21.06%
Future PE
14.53x
Price in 2028
US$95.2
Trending Discussion
Recently Updated Narratives
AN
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Fair Value: US$37.42 42.6% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Fair Value: US$21.65 0.7% undervalued intrinsic discount
40 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement
Fair Value: US$70 69.3% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sarepta Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 06, 2026
- -6.76
- -7.43%
- -32.45%
- 72.7%
About SRPT
- Founded
- 1980
- Employees
- 835
- CEO
- WebsiteView website
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
